SCHIZOPHRENIA2001
Download
Report
Transcript SCHIZOPHRENIA2001
SCHIZOPRENIA
Incidence of SCHIZOPHRENIA:
World Health Organization (1992)
DEVELOPED
COUNTRIES
ROCHESTER, NY
MOSCOW, RUSSIA
AARHUS, DENMARK
DEVELOPING
COUNTRIES
AGRA, INDIA
CALI, COLUMBIA
IBADAN, NIGERIA
RESULTS: INCIDENCE OF
SCHIZOPHRENIA IS SIMILAR
ACROSS ALL CITIES
SOME STATISTICS:
1% OF U.S. POPULATION
1 in 3 PSYCHIATRIC HOSPITAL BEDS
$65 BILLION
DIRECT TREATMENT
SOCIETAL COSTS
hospitals and institutions
law enforcement and judicial system
FAMILY COSTS
TWO CATEGORIES OF
SYMPTOMS:
POSITIVE SYMPTOMS
THOUGHT DISORDERS
DELUSIONS-BELIEFS
CONTRARY TO FACTS
PERSECUTION
GRANDEUR
CONTROL BY OTHERS
PARANOIA
HALLUCINATIONS
Auditory most common
NEGATIVE SYMPTOMS
FLATTENED EMOTIONAL
RESPONSES
POVERTY OF SPEECH
LACK OF INITIATIVE
SOCIAL WITHDRAWAL
INABILITY TO
EXPERIENCE PLEASURE
COGNITIVE
DYSFUNCTIONS
NEGATIVE SYMPTOMS
These symptoms are similar to those observed
in people with FRONTAL LOBE DAMAGE.
NEUROLOGICAL DISORDERS
Catatonia
Abnormal visual pursuit
Staring, no eye contact with others
Altered blinking (too much or not at all)
Poor pupillary reflex
EVIDENCE FOR A BIOLOGICAL
BASIS FOR SCHIZOPHRENIA?
GENETIC DATA
PHARMACOLOGICAL DATA
BRAIN IMAGING DATA
DEVELOPMENTAL DATA
WHAT IS THE EVIDENCE?
GENETICS
THE GENETICS OF
SCHIZOPHRENIA
FAMILY STUDIES
TWIN STUDIES
MONOZYGOTIC TWINS ~ identical twins
DIZYGOTIC ~ fraternal twins
CONCORDANT
DISCORDANT
ADOPTION STUDIES
both twins SCHZO.
one twin SCHZO.
Kety (1994)
Denmark Adoptee Studies
1. 5.6% of the relatives of schizophenics were
diagnosed with schizo. or latent schizo.
2. 0.9 % of the relatives of normal adoptees
were diagnosed with these disorders
3. Schizo. More common in 1st degree relatives
- Schizophrenia in 1st degree relatives = 12%
- Schizophrenia in 2nd degree relatives = 2.2%
4. Biological relatives of schizophrenics show no
increased rate of other mental disorders
IMPORTANT POINTS TO REMEMBER
FROM TWIN STUDIES:
SCHIZOPHRENIA has a genetic component.
Genetics, however, is not the whole story.
Concordance rate far less than 100%.
Genetics may predispose an individual to
developing SCHIZOPHRENIA.
Environmental factors may interact with
genetics to increase susceptibility.
Therefore, there must be “unexpressed,
dormant, schizophrenic genes”
PHARMACOLGICAL DATA: THE
DOPAMINE HYPOTHESIS
Origins of antipsychotic drug development:
Laborit ~ accidentally found that antihistamines
reduced anxiety in presurgical patients.
Charpentier ~ chlorpromazine “quieted
hyperactive” mental patients & “activated
withdrawn” mental patients.
Since the early drugs (e.g., chlorpromazine and
reserpine) produced Parkinsonian effects, these
drugs were believed to act on the dopamine
system.
ADDITIONAL EVIDENCE FOR
THE DOPAMINE HYPOTHESIS
Cocaine, amphetamine, L-Dopa
Positive Symptoms of Schizophrenia
(blocked by antipsychotics)
Suggestion:
Antipsychotics = dopamine receptor antagonists
(neuroleptics)
SNYDER (1976,1978)
Examined the ability of antipsychotic
(neuroleptic) drugs to bind to dopamine
receptors.
Examined the relationship of a drug’s receptor
binding affinity with its potency to reduce
schizophrenic symptoms.
SNYDER (1976, 1978)
Extracted neostriatum from calf brains
- neurons contain dopamine receptors
Exposed neurons to radioactive dopamine
Washed away unbound dopamine
Measured amount of radioactivity in the
neostriatum = measure of dopamine receptor
binding
Measured the ability of various antipsychotics
to block the binding of radioactive dopamine.
SNYDER (1976, 1978)
RESULTS:
Highly clinically effective antipsychotics had a
high binding affinity for dopamine receptors.
Less effective antipsychotics had a lower affinity.
One exception = Haloperidol
- highly clinically effective for schizophrenia
- low binding affinity to striatal dopamine
receptors
The Haloperidol Puzzle
Striatal Neurons
mostly D1 receptors
Chlorpromazine binds to D1 and D2 receptors
Haloperidol binds preferentially to D2 receptors
Chlorpromazine = Phenothiazines = D1, D2
Haloperidol = Butyrophenones = D2 selective
The Dopamine Receptors
D1
D2a
Haloperidol binds best to D2 receptors
D2b
D3
D4
Clozapine binds to D4 receptors
D5
Clozapine = an atypical neuroleptic. No
Parkinsonian side effects. High binding to D4
WHAT IS WRONG WITH THE
DOPAMINERGIC SYNAPSE IN
SCHIZOPHRENICS?
POSSIBILITIES:
1. Increased release of dopamine?
- More excitatory input to dopamine-containing
neurons
- Fewer or defective autoreceptors on dopamine
neuron
2. Overabundance of dopamine
receptors on post-synaptic neuron?
- more response in postsynaptic neuron to
dopamine receptor activation
Where are the dopaminergic
abnormalities located?
The Neostriatum?
Amygdala?
Frontal cortex?
Nucleus accumbens?
- D4 receptors located here
The Nucleus Accumbens
Are reinforcement/reward and
schizophrenia related?
-If reinforcement mechanisms are active at
inappropriate times, then inappropriate
behaviors (e.g., delusional thoughts) may be
reinforced.
-Elation/euphoria reported to occur at onset of
schizophrenic episode.
BRAIN ABNORMALITIES
AND SCHIZOPHRENIA
Since typical antipsychotics DO NOT alleviate
negative symptoms associated with
schizophrenia
and the negative symptoms are similar to
those produced by frontal lobe damage
…Then, maybe frontal lobe dysfunction
contributes to the negative symptoms of
schizophrenia.
Weinberger (1980’s – present)
Studied discordant identical twins:
SCHIZOPHRENIC twin showed enlarged
ventricles in 16 of 17 pairs.
SCHIZOPHRENICS, in general, have larger
ventricular to brain ratios (i.e., larger
ventricles, less brain).
Weinberger (1992)
Wisconsin Card Sorting Task (WCST)
WCST activates the lateral prefrontal lobe
Patients with lateral prefrontal lobe damage
Deficient in WCST
Identical twins: discordant for SCHIZOPHRENIA
PET scan during WCST
Weinberger, 1992 - WCST
Weinberger (1992)
RESULTS:
SCHIZOPHRENIC twin impaired on task, just
like people with prefrontal lobe damage
SCHIZOPHRENIC twin shows hypoactivity in
frontal lobe (decrease blood flow vs. unaffected
twin)
Many SCHIZOPHRENICS are impaired on task
and show frontal lobe hypoactivity
Wolkin et al. (1992)
Correlated the NEGATIVE SYMPTOMS with
FRONTAL LOBE metabolism (e.g., activity)
in SCHIZOPHRENIC patients.
RESULTS: The more severe the negative
symptoms, the less the metabolism (activity)
However, NO GROSS STRUCTURAL
ABNORMALITIES in SCHIZOPHRENICS!!!!!!
WHAT ARE THE CAUSES
OF hypoFRONTALITY?
Abnormality in the development of frontal
lobe?
Benes et al. (1986,1991)
Took a closer look at the cells in the FRONTAL
CORTEX…
SCHIZOPHRENIC BRAINS vs NORMAL BRAINS:
Benes et al. (1991)
Abnormally LOW number of neurons in
LAYERS I and II (outer layers) of the
FRONTAL CORTEX.
Abnormally HIGH number of neurons in
LAYER V (deep layers)of the FRONTAL
CORTEX.
Suggest: Abnormalities NOT due to
degeneration (since levels of glia cells
normal) but due to DEVELOPMENTAL
abnormalities.
WHAT DEVELOPMENTAL FACTOR(S)
MAY CAUSE BRAIN ABNORMALITY?
A VIRUS?
GENETIC ABNORMALITY?
AN INTERACTION OF THE TWO?
Epidemiological Evidence for
an Environment influence
Mednick (1988)
- Helsinki, Finland
-1957 ~ Asian Flu Epidemic (Virus)
- Higher incidence of SCHIZOPHRENIA in
fetuses carried during the epidemic vs.
before epidemic
- KEY POINT: Fetuses whose mothers
developed the Flu during the 2nd trimester of
pregnancy had highest incidence of
schizophrenia as adults
WHAT HAPPENS DURING THE 2ND
TRIMESTER OF PREGNANCY?
Marked development of the neocortex
Cortex develops inside out:
Cells migrate to deep layers 1st.
Cells of the outer layers must migrate
through deep layers).
In the SCHIZOPHRENIC brain, cells destined
to be the outer layers of the cortex get
STUCK and never make it there.
ADDITIONAL SUPPORT FOR
DEVELOPMENTAL FACTORS…
Brach et al. (1992)
“CHRONO MARKERS” OR “FOSSILS” OF 2ND
TRIMESTER development: CORTEX AND FINGER
TIP DERMAL CELL MIGRATION
Studied: MONOZYGOTIC TWINS
- NON-SCHIZOPHRENIC PAIRS (n=7)
- SCHIZOPHRENIC DISCORDANT PAIRS
(n=23)
Measured: INTRA-TWIN
DIFFERENCES IN FINGER TIP RIDGE
PATTERNS
Brach et al. (1992)
RESULTS:
- NON-SCHIZOPHRENIC TWINS ALL HAVE
SAME FINGER PRINTS (not a lot of
differences).
- TWINS DISCORDANT FOR SCHIZOPHRENIA
have different finger prints!
Brach et al. (1992)
CONCLUDE:
- During the 2nd trimester of pregnancy,
something in the “environment” may
have differentially affected one twin but
not the other.
- Maybe it was a virus, but we still don’t
have the answer…
IN SUMMARY:
SCHIZOPHRENIA IS A BIOLOGICAL
DISEASE THAT MAY INVOLVE DISRUPTION
OF MANY SYSTEMS
FRONTAL CORTEX
DOPAMINE SYSTEMS
GENETIC, ENVIRONMENTAL AND
DEVELOPMENTAL FACTORS ARE
IMPORTANT FOR THE GENISIS OF THE
DISEASE
An Animal Model of
Schizophrenia??
Phencyclidine (PCP) – “angel dust”
Single ingestion
transient schizo. symptoms
Chronic use
long lasting schizo. symptoms
- social withdrawal
- flattened emotional responses
- hallucinations
- thought disorders
- delusions, paranoia
- Cognitive dysfunction, hypofrontality
Jentsch et al. (1997)
Effects of chronic PCP exposure in monkey
- twice/day for 14 days
Measured:
- cognition dependent on normal frontal lobe
dopamine levels
- frontal lobe dopamine utilization
Task – “Object Retrieval with a Detour” task
-transparent box with one open side
-open side oriented to the front, right or left of monkey
-box contains a treat
-monkey retrieves treat from one orientation (front)
Jentsch et al. – cont.
- re-orient the box opening to left
- monkey must redirect response without touching a
closed side to be successful
Design:
- give PCP or saline for two weeks, then stop treatment
- administer task from 7-28 days later
Results:
- PCP-treated monkeys showed perseveration when
box is re-oriented. They keep making the original
response
Jentsch et al. – cont.
Important Points:
- Deficits identical to those seen in monkeys w/
frontal lesions or frontal dopamine depletion
- Deficits similar to those seen in schizophrenics
or humans with frontal lobe lesions
Results: Dopamine Assay
- chronic PCP decreases dopamine utilization in
the prefrontal cortex
Jentsch et al. – cont.
Dopamine antagonists
exacerbate cognitive
dysfunction in schizo.
Suggests:
- a subset of schizo. symptoms may be due to
dopamine hypoactivity in frontal lobes
Clozapine =atypical neuroleptic
- improves performance of chronic PCP
monkeys in object retrieval task
-increases basal dopamine concentration in frontal
cortex